Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52

2006 ◽  
Vol 98 (2) ◽  
pp. 217-222 ◽  
Author(s):  
James N. Ingle ◽  
Vera J. Suman ◽  
James A. Mailliard ◽  
John W. Kugler ◽  
James E. Krook ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Treatment Group ◽  
Adjuvant Therapy ◽  
Randomized Trial ◽  
Postmenopausal Women ◽  
North Central ◽  
Estrogen Receptor Positive ◽  
Group Trial ◽  
Positive Breast Cancer

Randomized Trial of Observation Versus Adjuvant Therapy With Cyclophosphamide, Fluorouracil, Prednisone With or Without Tamoxifen Following Mastectomy in Postmenopausal Women With Node-Positive Breast Cancer

1989 ◽  
Vol 7 (1) ◽  
pp. 145-145
Author(s):  
James N. Ingle ◽  
Lloyd K. Everson ◽  
H. Sam Wieand ◽  
J. Kirk Martin ◽  
Henry J. Votava ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Randomized Trial ◽  
Clin Oncol ◽  
Postmenopausal Women ◽  
Median Dose ◽  
The Mean ◽  
Made In ◽  
September Issue ◽  
Positive Breast Cancer

In Table 4 of the manuscript by Ingle et al published in the September issue (J Clin Oncol 6:1388–1396, 1988) an error was made in the dosage of tamoxifen. The planned dose should have read 140 mg/wk; the mean dose, 125 mg/wk; and the median dose, 140 mg/wk.

Sign in / Sign up

Export Citation Format

Share Document